A New Synthetic Steroid, Osaterone Acetate (TZP-4238), Increases Cortical Bone Mass and Strength by Enhancing Bone Formation in Ovariectomized Rats

DOI PDF Web Site 被引用文献3件
  • Hiroaki Fuse
    Teikoku Hormone Manufacturing Co., Kanagawa, Japan
  • Seiji Fukumoto
    Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo, Japan
  • Hideyuki Sone
    Teikoku Hormone Manufacturing Co., Kanagawa, Japan
  • Yoshiko Miyata
    Teikoku Hormone Manufacturing Co., Kanagawa, Japan
  • Tomoyuki Saito
    Teikoku Hormone Manufacturing Co., Kanagawa, Japan
  • Konosuke Nakayama
    Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo, Japan
  • Hiroo Takahashi
    Teikoku Hormone Manufacturing Co., Kanagawa, Japan
  • Toshio Matsumoto
    First Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima, Japan
  • Etsuro Ogata
    Japanese Foundation for Cancer Research, Tokyo, Japan

この論文をさがす

抄録

<jats:title>Abstract</jats:title> <jats:p>A new synthetic steroid, 17α-acetoxy-chloro-2-oxa-4,6-pregnadiene-3,20-dione (osaterone acetate, TZP-4238), has a potent antiandrogenic and gestagenic action with virtually no estrogenic and androgenic activity in their classical target organs. In the present study, the effects of TZP-4238 on the structure, strength, and turnover of the rat long bones were examined. Female Wistar rats at 12 weeks of age were ovariectomized (OVX) and treated with TZP-4238 or 17β-estradiol (E2) every day for 12 weeks. TZP-4238 significantly increased the diameters and maintained bone mineral density (BMD) of the femur of OVX rats. Although the BMD of the total femur was higher in E2-treated rats than that in TZP-treated rats, E2 did not increase the diameters of the femurs. To examine the effects of TZP-4238 and E2 on the BMD of different regions of the femur, the BMD was further analyzed by dividing it into 20 regions of equal longitudinal length. E2 increased the BMD of the distal and proximal metaphysis, regions rich in trabecular bone, but had no effect on the BMD of the femoral diaphysis compared with OVX control rats. In contrast, 2.5 and 12.5 mg/kg TZP-4238 increased the BMD of the femoral diaphysis, regions rich in cortical bone, but did not affect the BMD at the distal metaphysis. In agreement with the changes in the BMD of different regions of the femur, TZP-4238 but not E2 increased the physical strength of the femoral diaphysis assessed by a three-point bending test. Histomorphometric analyses of the cross-sections of the tibia revealed that TZP-4238 increased but E2 reduced the periosteal bone formation rate compared with OVX rats. In addition, TZP-4238 caused an increase in serum bone alkaline phosphatase with only a mild and transient decrease in urinary deoxypyridinoline excretion, while E2 reduced both of these parameters. These results demonstrate that TZP-4238 increases the dimension, BMD, and physical strength of the rat long bones by enhancing cortical bone formation, while estrogen maintains trabecular BMD by inhibiting bone resorption. Because the physical strength of long bones is affected by cortical bone mass and geometry, the effect of TZP-4238 on cortical bone may have a potential for the treatment of osteoporosis with reduced cortical bone formation.</jats:p>

収録刊行物

被引用文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ